RETRACTED ARTICLE: Correlation of CD44v6 expression with ovarian cancer progression and recurrence
Open Access
- 8 April 2013
- journal article
- retracted article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 13 (1), 182
- https://doi.org/10.1186/1471-2407-13-182
Abstract
Background Previously some groups demonstrated that CD44 variant 6 (CD44v6) is correlated with progression and metastasis of ovarian cancer. However, a number of other groups failed to find such an association. Moreover, epithelial ovarian cancer is known to easily metastasize to distinct sites such as the pelvic and abdominal cavities, but the potential association of CD44v6 expression with site-specific metastasis of ovarian cancer has not been explored. This study sought to evaluate the expression of CD44 standard (CD44s) and CD44v6 in primary, metastatic and recurrent epithelial ovarian cancer to explore the potential association of CD44s and CD44v6 with tumor progression and recurrence. Methods Tumor specimens were procured from patients with advanced (FIGO III, G3) and recurrent ovarian serous adenocarcinoma. CD44s and CD44v6 expression in the tumor tissues was evaluated by real-time RT-PCR and Western blot. Moreover, serum soluble CD44s or CD44v6 concentrations of early stage (FIGO I, G1), advanced (FIGO III, G3) and recurrent ovarian serous adenocarcinoma patients were determined by enzyme-linked immunosorbent assays (ELISA). CD44v6 expression in a different set of tumor samples on an ovarian cancer tissue chip was evaluated by immunohistochemistry (IHC) and the correlation of CD44v6 expression with clinicopathologic features was analyzed. Finally, the effects of knockdown of CD44v6 in SKOV3 cells on cell adhesion, invasion and migration were assessed. Results The expression of CD44v6, but not CD44s, is up-regulated in recurrent ovarian serous cancer compared to advanced primary tumor. CD44v6 expression is also preferentially increased in the tumor at the abdominal cavity metastasis site of advanced diseases. Consistently, serum soluble CD44v6 levels of recurrent ovarian cancer were higher than those of early stage and advanced primary diseases. The IHC data demonstrate that CD44v6 expression is correlated with clinicopathologic features and tumor progression. Lastly, knockdown of CD44v6 decreases the adhesion and migration but not invasion capacities of SKOV3 cells. Conclusions CD44v6 expression levels are associated with epithelial ovarian cancer progression, metastasis and relapse. Moreover, serum soluble CD44v6 may be used as a potential marker for identifying tumor relapse. Finally, CD44v6 may play a role in ovarian cancer metastasis by mediating tumor cell adhesion and migration.Keywords
This publication has 43 references indexed in Scilit:
- CD44s and CD44v6 in Diagnosis and Prognosis of Human Bladder CancerUltrastructural Pathology, 2012
- Rethinking ovarian cancer: recommendations for improving outcomesNature Reviews Cancer, 2011
- Serum CD44 levels and overall survival in patients with HER2-positive breast cancerBreast Cancer Research and Treatment, 2011
- Role of Versican, Hyaluronan and CD44 in Ovarian Cancer MetastasisInternational Journal of Molecular Sciences, 2011
- The genesis and evolution of high-grade serous ovarian cancerNature Reviews Cancer, 2010
- The biology of ovarian cancer: new opportunities for translationNature Reviews Cancer, 2009
- Shedding Light on Proteolytic Cleavage of CD44: The Responsible Sheddase and Functional Significance of SheddingJournal of Investigative Dermatology, 2009
- Significance of CD44v6 expression in gynecologic malignanciesJournal of Obstetrics and Gynaecology Research, 2006
- Biology of fetal wound healing: Hyaluronate receptor expression in fetal fibroblastsJournal of Pediatric Surgery, 1994
- Localization of hyaluronan in mouse embryos during implantation, gastrulation and organogenesisDifferentiation, 1993